Century Therapeutics Inc
Research Century Therapeutics Inc (IPSC) on Bullrun: market cap USD 391.37M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIPSC
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 391.37M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 107.79M
- Free cash flow-USD 25.85M
Valuation Snapshot
latest market cap is USD 391.37M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 109.16M | -USD 9.58M | -USD 104.72M | n/a | -0.14 | USD 61.85M | USD 43.57M | USD 158.94M |
| FY2024 | USD 6.59M | -USD 126.57M | -USD 110.29M | n/a | -1.61 | USD 58.44M | USD 53.83M | USD 161.36M |
| FY2023 | USD 2.24M | -USD 136.67M | -USD 102.08M | n/a | -2.3 | USD 47.32M | USD 48.17M | USD 184.75M |
| FY2022 | USD 5.20M | -USD 130.93M | -USD 16.55M | n/a | -2.96 | USD 84.27M | USD 3.74M | USD 302.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 391.37M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 87.52M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 86.69M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 198.65M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 302.54M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 872.39M | n/a | n/a | n/a |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Century Therapeutics Inc's market cap?
Century Therapeutics Inc's market capitalization is USD 391.37M.
What does Century Therapeutics Inc do?
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.